At the ASCO 2019 annual meeting, Alona Zer discusses the preliminary results from the interim analysis of a phase II study of nivolumab and ipilimumab in previously treated progressive Classic Kaposi Sarcoma (CKS) (NCT03219671).
1. Could you tell us a little about Classic Kaposi Sarcoma (CKS) and its prognosis? (0:04)
2. What is the rationale for using immune checkpoint inhibitors in patients with CKS? (0:35)
3. What are the limitations of current treatment options for CKS? (1:13)
4. What were the efficacy and safety findings of the phase II study investigating nivolumab and ipilimumab in patients with CKS? (1:50)
5. Which patients are most likely to respond to nivolumab plus ipilimumab? (02:37)
Speaker disclosure: Alona Zer has received a research grant and participated in an advisory board for BMS.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Sarcoma
Durvalumab + tremelimumab vs. doxorubicin in soft tissue sarcoma – MEDISARC study: Viktor Grünwald, ESMO 2023
To further understand the potential of durvalumab (DUR) plus tremelimumab (TRE) in the treatment of soft tissue sarcoma (STS) we spoke with Prof. Viktor Grünwald (University Hospital Essen, Germany). At ESMO 2023, Prof. Grünwald presented results from the MEDISARC trial (NCT03317457), a study designed to test whether DUR + TRE improved overall survival compared to […]
Brian Van Tine, ASCO 2021: Findings from the APROMISS Study
We were delighted to talk with Dr Brian Van Tine (Washington University School of Medicine, Saint Louis, MO, US) around the APROMISS study, investigating the efficacy and safety of AL3818 hydrochloride monotherapy in patients with metastatic or advanced synovial sarcoma. The abstract ‘A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects […]
Brian Van Tine, ESMO 2019 – Pazopanib in soft tissue sarcomas
Brain Van Tine (Washington University in St Louis) joins us to discuss the results of the phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy (NCT02300545). Questions 1. What are the limitations of standard first-line chemotherapy in the treatment of soft […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!